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MUTASI-MUTASI BRCA1, BRCA2 DAN HUBUNGKAITAN 
DENGAN CIRI-CIRI KLINIKOPATOLOGIKAL  DI 
KALANGAN WANITA YANG MENGHIDAP  BARAH 




Pengenalan: Mutasi BRCA1 dan BRCA2 telah dikenalpasti mempunyai hubung kait 
dengan kanser payudara pada usia awal dan ciri-ciri klinikal dan patologi yang 
buruk. Setakat ini, terdapat kekurangan dalam penyelidikan yang mengkaji 
hubungan antara jenis-jenis mutasi BRCA1/2 dan ciri-ciri klinikal dan patologi barah  
payudara di Malaysia. Oleh itu, tujuan kajian ini adalah untuk memastikan sama ada 
terdapat perbezaan antara jenis-jenis mutasi BRCA1/2 dari segi ciri-ciri klinikal dan 
patologi barah payudara di kalangan wanita-wanita yang mengalami penyakit ini 
pada usia awal. 
 
Metodologi: Tujuh puluh wanita berusia 40 dan ke bawah yang telah didiagnosa 
dengan barah payudara dan menjalani pemeriksaan susulan di Hospital Seberang 
Jaya, Pulau Pinang, telah direkrut untuk kajian ini. Ciri-ciri klinikal (umur, etnik, 
rawatan adjuvan, sejarah keluarga berkenaan kanser payudara dan ovary) dan 
patologi (reseptor untuk estrogen, progresteron, HER2 dan ketumbuhan yang 
negative untuk kesemua jenis reseptor, peringkat dan gred ketumbuhan) telah 
diperolehi secara retrospektif daripada penilitian rekod perubatan. Tiga mililiter 
darah telah diambil daripada setiap subjek yang kemudiannya digunakan untuk 
 xvii 
 
pengekstrakan DNA. DNA ini kemudian diskrin untuk mutasi titisan germa bagi gen 
BRCA1 (exon 11, 13 dan 16) dan BRCA2 (exon 10 dan 11) dengan menggunakan 
tindakbalas berantai polymerase spesifik alel. 
 
Keputusan: Kelaziman mutasi BRCA2 sahaja dan mutasi campuran BRCA1 dan 
BRCA2 adalah 28.6% (95% selang keyakinan: 18.3%, 39.2%) dan 71.4% (95% 
selang keyakinan: 60.8%, 80.2%). Tiada BRCA1 atau BRCA2 gen jenis liar dan 
mutasi pada BRCA2 sahaja  didapati dikalangan subjek kajian ini. Tiada hubungkait 
yang ketara antara jenis mutasi BRCA (BRCA2 sahaja dibandingkan dengan 
kombinasi mutasi BRCA1 dan BRCA2) daripada segi ciri-ciri klinikal dan patologi 
ketumbuhan payudara. Walaubagaimanapun, tiga mutasi BRCA1 (3232A>G 
(rs16941, exon 11), 3667A>G (rs16942, exon 11) dan 4427T>C (rs1060915, exon 
13) mempunyai hubungkait ketara dengan kumpulan saiz ketumbuhan peringkat 
lanjut (nilai p  = 0.032, 0.049 dan 0.043). Selain itu, mutasi pada posisi 3232A>G 
mempunyai hubungkait ketara dengan ketinggian tahap risiko untuk ketumbuhan 
payudara yang negatif untuk reseptor HER2 (nisbah ganjil: 7.50 (95% selang 
keyakinan: 1.439, 39.089), nilai p = 0.017) dan yang berstatus negatif untuk kesemua 
reseptor hormon (nisbah ganjil: 4.375 (95% selang keyakinan: 1.193, 16.038), nilai p 
=0.042). Tiada hubungkait ketara didapati antara genotip mutasi BRCA2 dan ciri-ciri 
klinikal dan patologi ketumbuhan payudara. 
 
Kesimpulan: Kombinasi mutasi BRCA1 dan BRCA2 mempunyai kelaziman 
tertinggi, diikuti mutasi BRCA2 sahaja. Tiga mutasi titisan germa BRCA1 
mempunyai hubungkait ketara dengan kumpulan saiz ketumbuhan peringkat lanjut 
manakala hanya satu mutasi BRCA1 mempunyai hubungkait ketara dengan 
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ketumbuhan yang negatif untuk reseptor HER2 dan berstatus negatif untuk kesemua 
reseptor hormon. Walaubagaimanapun, lebih banyak kajian diperlukan untuk 
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Introduction: BRCA1 and BRCA2 mutations have been associated with early-onset 
breast cancers and adverse clinico-pathological features. To date, there is paucity of 
studies in Malaysia investigating the relationship between types of BRCA1/2 
mutations and clinicopathological characteristics of breast cancers. This study 
therefore aims to ascertain whether there are differences between different types of 
BRCA1/2 mutations in terms of clinico-pathological attributes of breast cancers 
amongst females with early-onset breast cancers in Malaysia. 
 
Methodology: Seventy females aged 40 or less with confirmed breast cancer 
diagnosis that underwent follow-ups at Seberang Jaya Hospital, Penang were 
recruited into this study. Clinical (age, ethnicity, stage, neo adjuvant therapy, family 
history of ovarian and breast cancers) and pathological (ER, PR, Her2 status, triple 
negativity, tumour grades and stages) characteristics of the breast cancers were 
obtained by retrospectively reviewing the medical records. Three mls of blood was 
taken from each subject and subjected to DNA extraction. These were then screened 
for germline mutations of BRCA1 gene (exons 11, 13 and 16) for BRCA2 gene 




Results: The prevalence of BRCA2-only and combined BRCA1 and BRCA1 
mutations were 28.6% (95% CI: 18%, 39.2%) and 71.4% (95% CI: 60.8%, 82.0 %), 
respectively. No wild-type BRCA1 or BRCA2 and BRCA1-only mutations were 
observed in this study cohort. No significant associations were found between types 
of BRCA mutations (BRCA2-only mutations vs combined BRCA1 and BRCA2 
mutations) and clinico-pathological characteristics of breast tumour. However, three 
BRCA1 mutations (3232A>G (rs16941, exon 11), 3667A>G (rs16942, exon 11) and 
4427T<C (rs1060915, exon 13) were significantly associated with a more advanced 
tumour size group (p values = 0.032, 0.049 and 0.043, respectively). Besides, 
3232A>G (rs16941, exon 11) mutation was also significantly associated with higher 
risk of HER2-negative (OR 7.50 (95% CI: 1.439, 39.089), p value = 0.017) and 
triple negative breast carcinoma (OR 4.375 (95% CI: 1.193, 16.038), p value 
=0.042). No significant associations were found between BRCA2 genotypes and 
clinico-pathological features of breast carcinoma. 
 
Conclusion: Combined BRCA1 and BRCA2 mutations are the most prevalent types 
of BRCA mutations amongst females with early onset breast cancers, followed by 
BRCA2-only mutations. Three BRCA1 germline mutations were found to be 
significantly predictive of a more advanced tumour size group whilst only one 
BRCA1 mutation was significantly associated with HER2-negative and triple 
negative breast tumours. Nevertheless, further studies are warranted to address the 






1.1 EPIDEMIOLOGY OF BREAST CANCER 
Around the globe, cancer of the breast is the most frequently encountered 
cancer types in females. In the United States alone, it was estimated that 235,030 
incident cases of malignant breast cancer, 62,570 carcinomas-in-situ and 40,430 
deaths secondary to breast malignancy would occur in 2014 (Siegel et al. 2014). 
Breast cancer is implicated for the highest proportion of annual new cancer cases in 
female (29%) and second only to carcinoma of the lung and bronchus as the reason 
for cancer-specific mortality (15%) (Siegel et al. 2014). So far, the incidence of 
breast cancer has remained stable since 2005, after a sharp decline from 1999 to 
early 2005. This downward trend of breast cancer incidence may be attributable to 
the diminution of hormone replacement therapy (HRT) use among postmenopausal 
women (Ravdin et al.  2007). Nevertheless, the trend of breast cancer in young 
women is quite alarming. According to the analyses of Johnson, Chien & Bleyer 
(2013) which was based on Surveillance, Epidemiology and End Results (SEER) 
data obtained from 1976 to 2009, there is a statistically significant increase in the 
incidence of metastatic breast cancer among young women (defined as females in the 
age group of 25-39 years) in the United States (1.53 per 100,000 in 1976 to 2.53 per 
100,000 in 2009, p value <0.001). Due to this alarming trend, it is critical to further 
the understanding and resolve the impending controversies with respect to the 
mechanistic and pathological basis of early-onset breast malignancy. 
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In Malaysia, the quality and contemporariness of breast cancer data provided 
by the National Cancer Registry (NCR) is still mediocre and of dismal standard. The 
only credible data on breast cancer incidence was provided by Dahlui, Ramli and 
Bulgiba (2011) who showed the declining trend of breast cancer incidence from 
2003 to 2006 (46.2 per 100,000 vs 39.3 per 100,000). The only reported incidence of 
breast cancer in young females was by Pathy and colleagues (2011), who found a 
staggering 51 percent of females developed breast cancer at the age of 50 years or 
below. Nevertheless, such finding may be misleading since the analyses were based 
on the combined breast cancer cases in both Malaysia and Singapore and the 
different age limit used for defining early-onset breast cancer. The closest estimate, 
despite its outdated nature, is therefore the breast cancer statistics as reported by the 
NCR in 2007. According to NCR report, approximately 50% of breast cancer cases 
amongst women aged 50 or less and 16.8% of women under 40 years of age were 
affected by breast cancer (National Cancer Registry 2007). This estimate is thus not 
that far from what has been documented by Pathy et al.  (2011). With regard to racial 
distribution of breast cancer cases, the Chinese have the highest age-standardized 
breast cancer incidence rate (59.7 per 100,000), followed by the Indians (55.8 per 
100,000) and Malays (39.9 per 100, 000) (Yip, Mohd Taib, Mohamed 2006). Most 
of them were at the late stage of diagnosis (56.1% in stage III and IV at diagnosis) 
which was due to delayed diagnosis (Yip, Mohd Taib, and Mohamed, 2006). 
According to Bachok and associates (2011), use of alternative therapy, negative 
attitude towards treatment and false-negative diagnostic results are the associated 





1.2 THE HISTOLOGICAL PERSPECTIVE OF BREAST CANCER 
 Breast cancer can be classified by several ways but the most common 
classification system identified two main types of invasive breast cancer; infiltrating 
ductal and infiltrating lobular carcinomas. Other tumour types such as medullary, 
tubular and mucinous carcinomas are considered less common and therefore will not 
be discussed in great details. 
 Invasive ductal carcinoma of no special type (NST) or not otherwise 
specified (NOS) is considered as the most common type of malignant breast 
pathology. It was estimated that this type of breast cancer was found in between 47% 
and 75% of all malignant breast cancer cases, depending upon the cohorts from 
whom data was obtained (Schnitt et al, 2003). The identification or confirmation of 
this tumour histology is usually made per exclusionem (diagnosis of exclusion).  On 
gross appearance, invasive ductal carcinoma has a scirrhous or stellate shape with 
solid gray-white nodular mass that can either be well-demarcated or in poorly-
circumscribed shape. On light microscopy, infiltrative mammary carcinoma of NST 
does not have particular features that may help pinpoint to its identification. The 
malignant epithelial cells appear to be organized in cords, tightly-cohesive nests, 
sheets and tubules that invade the fibrotic stromal part of the breast in a disorderly 
manner. 
 The second type of infiltrative breast cancer is the invasive lobular 
carcinoma. Classically, this tumour type is identified by its two most distinguishing 
characteristics; cytological features and invasive pattern. Invasive lobular carcinoma 
(ILC) has cytological characteristics that closely resemble lobular carcinoma-in situ: 
regular, flat-shaped nuclei with intracytoplasmic lacunae (Battifora, 1975).  Besides, 
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its distinctive invasive pattern, targetoid growth pattern, makes it possible to be 
accurately and easily identified by histopathologist. There are also other variants of 
ILC such as solid, alveolar, mixed or pleomorphic types (Martinez & Azzopardi 
1975). They are different to the classical ILC in terms of their nuclei shape and lack 
of targetoid growth features upon microscopic examination.  This type of breast 
carcinoma has an intermediate prognosis (5-year survival of 70% to 80%), better 
than the prognostically-poor ductal carcinoma of no special type but much worse 
than the excellent prognosis of tubular carcinoma. 
1.3 RISK FACTORS OF BREAST MALIGNANCY 
Five major classes of risk factors have been identified as the determinants of 
breast cancer risk; types of dietary intake, exposure to ionizing radiation, use of 
exogenous hormone and reproductive factors, and genetic predisposition to breast 
cancer. Moderate-to-excessive alcohol intake is the most well-established factor for 
breast cancer (Chen et al. 2011). Other dietary factors for instance low fat and high 
fruit and vegetable intake have also been found to be generally protective against 
breast cancer (Linos & Willett 2007). Nevertheless, results from the multicentre 
Women’s Healthy Eating and Living (WHEL) trial demonstrated no significant 
decrease of breast cancer recurrence in subjects who consumed low fat or high fruit 
and vegetable diet (Pierce et al. 2007). This observation is however at variance with 
the findings of the much larger Women’s Intervention Nutrition Study (WINS trial) 
which showed a lowering of breast cancer recurrence risk among subjects 
randomized to low-fat dietary regime which may be attributed to moderate weight 
loss secondary to reduced calorie intake (Hoy et al. 2009). This discrepancy of 
findings, however, requires further investigations to solidly resolve the divergent 
conclusions made by the authors.  
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In regard to ionizing radiation, higher risk of breast malignancy is found in 
those exposed to either therapeutic (radiotherapy) or accidental exposure to radiation 
(e.g. Japanese survivors of atomic bomb, nuclear meltdown in Chernobyl). In the 
former, breast cancer risk has been found to be increased in recipients of extended 
field radiation therapy for Hodgkin’s Lymphoma. The age at first radiotherapeutic 
exposure was found to be the principal factor in modulating breast cancer risk, with 
the highest and lowest risks were found among females who received mantle field 
radiotherapy at puberty and postmenopausal females, respectively (Swerdlow et al  
2012, Ronckers, Erdmann & Land 2005). 
The use of exogenous oestrogen in HRT has been singled out as one of the 
chief determinants of breast cancer. A combined analysis of data from the large 
multicentre Women’s Health Initiative (WHI) study and other 51 additional studies 
revealed that the use of exogenous hormone was associated with a slight increase in 
risk of breast cancer development (Collaborative Group on Hormonal Factors in 
Breast Cancer 1997). Nonetheless, this small increase in breast cancer risk was 
counterbalanced by the decrease in colon and ovarian cancer risk of similar 
magnitude, resulting in no increase of overall breast cancer risk among HRT users 
(Colditz & Hankinson 2005). Other studies found the link between types and timing 
of HRT (oestrogen only vs combined, right after menopause vs delayed HRT 
institution) and breast cancer occurrence, with the highest risk found in those who 
were started on HRT soon after menopause occurs (Beral et al. 2011). All in all, with 
the observations made by Ravdin et al., (2007), the use of HRT is associated with a 
slight but significant increase risk in breast malignancy especially in those who are 




Late age of menopause, early menarche, nulliparity and late age at first full-
term birth (above 30 years of age) had been systematically found to be the major 
reproductive factors for breast cancer (Kelsey, Gammon & John 1993, McPherson, 
Steel & Dixon 2000). This finding is in coherence with the duration of lifetime 
exposure to oestrogen and the fact that breast cancer risk is higher in postmenopausal 
women who had oestradiol levels in the highest quartile (Farhat et al. 2011). Besides 
that, obese women are also at a greater risk of breast cancer due to higher circulating 
oestrogen and endogenous insulin levels than females with normal body mass index 
(BMI) (Hvidtfeldt, 2012). Therefore, this class of breast cancer aetiologies can be 
considered as the mechanistic “hinges” or the convergence point in the complex 
interplay of other risk factors within the web of causality for breast malignancy. 
The roles of genetic predisposition in breast cancer development will be 















2.1 INHERITED BREAST CANCER SYNDROME 
 Inherited breast cancer syndrome has been defined as early-onset breast 
cancer (median age at diagnosis: 45 years, may occur as early as early 20s with an 
elevated risk for the whole lifetime of an individual), a nimiety of familial bilateral 
breast cancer cases, a larger occurrence of primary cancers in the hereditary breast 
and ovarian cancer (HBOC) spectrum and an autosomally-dominant feature of 
inheritance of cancer susceptibility genes (Lynch et al. 1994). This hereditary form 
of breast cancer differs from sporadic breast cancer in that the latter cases occur in 
females without positive family history of breast cancer affecting two consecutive 
generations (e.g parents, paternal and maternal aunts, uncles or grandparents, 
siblings) (Lynch et al. 2009). On the other hand, breast cancer with a positive family 
history of carcinoma of the breast involving at least one second or first-degree family 
members but lack of other features (eg variable age of onset) that may fit them in the 
inherited breast cancer syndrome category is classified as familial breast cancer 
(Lynch et al. 2009).   
 Due to the aggressive nature of hereditary breast carcinoma, genetic 
counselling and screening practices are compulsory for the management of this 





1) Highly-penetrant genes such as Breast cancer susceptibility 1 (BRCA1), Breast 
cancer susceptibility 2 (BRCA2), and Tumour protein p53 (TP53) 
2) Intermediately-penetrant genes, for instance Checkpoint Kinase-2 (CHEK2) and 
Ataxia Telangiectasia Mutated (ATM) 
3) Low penetrant genes (e.g Fibroblast Growth Factor receptor-2 (FGFR2) and 
(Thymocyte selection-associated high mobility group box) TOX). 
In the next section, BRCA1 and BRCA2 mutations will be discussed in greater details 
with exploration on the correlation between mutations in the respective genes with 
their associated clinicopathological characteristics. 
 
2.2 BRCA1 AND BRCA2 GENES: THE CARETAKERS OF HUMAN 
GENOME 
 BRCA1, a tumor suppressor gene, is located in the long arm of chromosome 
17 (17q21). It codes for a protein product that plays a critical role in repairing DNA 
double-strand breaks. It has 22 exons which encrypt for a protein of the size of 1863 
amino acids. So far there were 1643 discrete mutations, polymorphisms and variants 
of this gene has been identified, of which 890 are discovered and reported in single 
individual only (ie. only one person was found to harbour each mutation, 
polymorphism or variant). BRCA1 gene is one of the major causes for breast and 
ovarian cancer in females under 40, accounting for 5.3% and 5.7% of all breast and 
ovarian cancer cases in that subgroup, respectively (Ford & Easton, 1995). The main 
types of mutations found in BRCA1 are frameshift, nonsense and splice mutations 
(Chen & Parmigiani, 2007). In a majority of cases, these mutations cause a non-
functional BRCA1 protein due to its premature shortening. For instance, a nonsense 
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mutation occurring in BRCA1 results in one of the codons of BRCA1 exons being 
replaced by a stop codon (Glu1541Stop, Gln1313Stop), leading to untimely 
truncation of the BRCA1 protein (Futreal et al. 1994, Miki et al. 1994). This will in 
turn result in a dysfunctional or non-functional BRCA1 protein that is unable to 
effectively repair double strand breaks in DNA (Miki et al.  1994). 
 Besides that, Easton and colleagues have discovered two distinct phenotypic 
variations of families affected by BRCA1 germline mutation using linkage analyses: 
1) families with high number of cases with ovarian carcinoma (84% of them have 
developed ovarian carcinoma by the age of 70 years), 2) those with relatively low 
number of ovarian carcinoma (ovarian carcinoma occurring in 32% of cases by 70 
years of age). Furthermore, Gayther et al., (1995) also reported a statistically-
significant association was found between the position of BRCA1 mutation and 
breast to ovarian cancer ratio of incidence occurring in each of the family Mutations 
in the last third of the gene (at 3’ position) are associated with a lower risk of ovarian 
cancer (Thompson et al. 2002, Gayther et al. 1995, Holt et al 1996). 
 The mechanism by which BRCA1 protein assists in repairing double strand 
breaks in DNA is quite complex. BRCA1 primarily acts as the initial “sensor” of the 
existence of DNA double-strand break or gap which is then relayed to the other 
regulators of DNA-repair machinery. The end product of this DNA-repair signalling 
cascade is DNA repair by homologous recombination. A vivid explanation on the 
molecular structure of BRCA1 protein is therefore fundamental to understand its 
functional role as the custodian of genomic integrity in human (Venkitaraman 2014). 
There are three main components of BRCA1 proteins that may explain further 
its role in DNA double-strand break repair; 1) a Really Interesting New Gene 
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(RING) domain at N-terminus 2) BRCA1 C-terminus (BRCT) domain at carboxyl 
(C) terminus, 3) a long central region between 170th and 1649th amino acid residues, 
flanked by the C and N termini (Venkitaraman, 2014). This long central region of 
BRCA1 protein is hypothesized to be an intrinsically-disordered region, a view that 
has been supported by both in-silico and experimental models (Mark et al. 2005).  
The RING domain, which is further stabilized by its heterodimerization with 
BRCA1-associated ring domain-1 (BARD1), possesses E3 ubiquitin ligase activity 
(Roy, Chun & Powell 2012, Wu et al. 1996). The activation of BRCA1-BARD1 
ligase activity is usually induced by erroneous DNA replication or exposure to 
genotoxic stress (Greenberg et al. 2006). This BRCA1-BARD1 ligase will then 
interact and polyubiquinate other proteins such as CtIP, histone H2A and H2AX 
(Thakar et al.  2010, Yu et al. 2006, Irminger-Finger & Jefford 2006). These 
proteins, especially CtIP, will then associate with BARD1-BRCA1 complex via the 
C-terminus of BRCA1 to form a BRCA1-CtIP complex (Wu et al. 2008). This 
BRCA1-CtIP complex will then initiate panoply of double strand break end resection 
to create overhung single-strand DNAs (ssDNA) that is vital for subsequent repair of 
double strand break by homologous recombination (Sartori et al. 2007, Limbo et al.  
2007). Besides, the BRCA1-CtIP complex activity will also lead to cell cycle arrest at 
G2/M phase, during which the repairing of DNA double-strand break can be 
effectively implemented (Wu et al. 2007). These crucial roles of BRCA1 RING 
domain in preventing tumourigenesis had been proven by Sankaran and co-workers 
(2006) who demonstrated missense mutations occurring inside BRCA1 RING 
domain will lead to the abolishment of BRCA1 ligase activity and thus culminating 
in overt tumour formation. 
 11 
 
The other parts of BRCA1 proteins also have great roles in initiating DNA 
double-strand break repair. The C-tandem repeat in BRCT domain mobilizes BRCA1 
protein to the damaged DNA sites (Venkitaraman, 2014). This initial recruitment is 
made feasible by the ability of C-terminus region of BRCT to bind to poly-ADP 
ribose (PAR) chains attached to the proteins at the DNA double strand break 
locations (Li et al 2013). This BRCA1 recruitment to the damage site is subsequently 
augmented by the binding of BRCA1 to the phosphopeptide motif of serine residue, 
which was generated by the activated DNA-damage-sensing tyrosine-kinase 
(Venkitaraman, 2014). Subsequently, using its BRCT domain, BRCA1 protein 
engages and regulates various macromolecular complexes activity and assembly 
which function as DNA damage sensors and repair executors at DNA damage sites 
and stalled replication forks (Greenberg et al. 2006). Eventually, this BRCA1-
associated macromolecular complex will displace 53BP1, a HR suppressant, from 
the DNA strand’s broken end thus initiating the repair of DNA damage via 
homologous recombination during the G2 phase of the cell cycle (Bouwman et al 
2010, Bunting et al. 2010). 
BRCA2 gene, on the other hand, is located on the long arm of chromosome 
13 (13q12.3). It consists of 27 coding regions (exons) with a size of 84 kilobases 
(kb) (Ioan et al. 2009) So far, more than 450 new BRCA2 mutations have been 
discovered which are disseminated over the whole span BRCA2 gene (Ioan et al. 
2009). Similar to BRCA1, founder mutations have also been characterized in several 
populations; for instance in Ashkenazi Jewish females, 185delAG and 6174delT are 
considered as among the first founder mutations and most prevalent BRCA2 
mutations ever described in such population (Struewing et al. 1995, Roa et al.  
1996). Like BRCA1, BRCA2 gene mutation is also associated with breast cancer at 
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early age and bilateral breast carcinomas. Interestingly, it is also associated with 
several types of cancer susceptibility syndrome such as the rare Fanconi anemia (FA) 
and Bloom syndrome (Patel et al.  1998). Its functional role as the caretaker of 
genomic integrity also lies in its ability to repair DNA double-strand breaks and thus 
preserving genomic fidelity during DNA replication (Ioan et al. 2009).   
For it to function effectively, BRCA2 proteins recruit RAD51, a DNA 
recombinase, as part of BRCA2-mediated DNA double-strand break repair 
machinery. BRCA2 binds to the RAD51 protein and ships it to the DNA damage site 
at which it is subsequently released (Gudmundsdottir & Ashworth, 2006). Then, 
RAD51 protein initiates the formation of nucleoprotein filament on single-sranded 
DNA (ssDNA). This RAD51-ssDNA nucleoprotein complex then induces synapsis 
with the homologous sister chromatid which allows the exchange of DNA strand 
between the chromatids (Venkitaraman, 2014). This results in a successful DNA 
double strand break repair via the error-free homologous recombination (Saeki et al. 
2006). 
2.3 BRCA1 AND BRCA2 MUTATIONS: GLOBAL AND LOCAL 
PERSPECTIVE 
 The first population whose BRCA1 and BRCA2 mutation status was fully 
characterized is the Ashkenazi Jews. Struewing et al. (1995) discovered the high 
prevalence of 185delAG frameshift mutation in 0.9% (95% CI 0.4-1.8) Asheknazi 
Jewish subjects. A study by Roa and associates (1996) which utilized a large number 
of Ashkenazi Jewish individuals (n=3000) as the study subjects corroborated the 
findings Struewing et al. (1995). They found that the carrier frequency of BRCA1 
mutations to be at 1.09% which was further supported by the results obtained by 
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Offit et al.(1996) who demonstrated that 20% of early-onset breast cancer cases in 
Ashkenazi Jewish females was found to harbour 185delAG mutation. This confirms 
the founder effects of such mutation in Ashkenazi Jews.  
 In other populations, varying numbers of novel BRCA1 mutations (with and 
without founder effects) were discovered. For instance, L63X and Q934X were 
found to be the most prevalent BRCA1 mutations in Japanese population (Liede & 
Narod 2002). Based on haplotyping of BRCA1, both mutations were thought to be 
derived from the same ancestors, thus confirming them as founder mutations in 
Japanese population (Sekine et al. 2001). Among the Pakistanis, the highly-prevalent 
European BRCA1 4814del4 frameshift mutation has been found in 15% of 
individuals with breast carcinoma. Besides that, one BRCA1 founder mutation 
(c.981_982delAT) had also been characterized in Southern Chinese breast cancer 
patients (Kwong et al. 2012) whilst 3478del5 and 5589del8 BRCA1 mutations were 
found to exhibit founder effects for Northern Chinese breast cancer subjects (Karami 
& Mehdapour,  2013). For subjects of Scandinavian origins, 1675delA and 1135insC 
mutations were found to be prevalent and possess the founder effects in Norwegian 
and Danish populations (Thomassen et al. 2008). Therefore, the types of BRCA1 
mutation vary from one population to another, signifying profound ancestral effects 
in the evolution of BRCA1 gene. 
 In our local setting, the prevalence of combined BRCA1 and BRCA2 
mutations is 20% (Yip et al. 2009). For BRCA1, 14 sequence alterations had been 
documented and reported by Toh et al. (2008), of which 3 are novel findings. One 
deleterious germline BRCA1 novel mutation (IVS3+2delT) was discovered by the 
researchers in one early-onset Malaysian Chinese breast cancer subject without 
obvious family history. One possible founder mutation (2846insA) has been 
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described by Lee et al. (2003) among Malay breast cancer patients residing in 
Singapore. A report by Thirthagiri et al. (2008) confirmed the heteregenous nature of 
BRCA1 mutation; 14 novels BRCA1 mutations were discovered with none of them 
were reported twice (ie. found in two unrelated individuals with early-onset breast 
cancer). Besides that, Lee and associates (2012) found similar frequencies of TP53, 
BRCA1 and BRCA2 mutations (5%, 6% and 11%, respectively). The authors 
suggested that the mutual coexistence of those three mutations, hence warranting 
TP53 to be included the full genetic screening for breast cancer. 
 With respect to BRCA2 mutations, as stated previously, 6174delT was the 
most common mutation found in Ashkenazi Jewish females with a prevalence rate of 
1.5% (Oddoux et al. 1996). Therefore, both 185delAG and 6174delT can be 
considered as the most prevalent BRCA1 and BRCA2 mutations in Ashkenzi Jewish 
women. However, BRCA2 mutation has generally a diminished penetrance than 
BRCA1 counterpart (Chen and Parmigiani, 2007). Hence, the risk of breast early-
onset breast carcinoma is lower in those who are positive for BRCA2 mutations than 
subjects with BRCA1 mutation (King et al.  2003). 
 In other populations, the frequency and types of BRCA2 mutations differ 
remarkably. In an unselected series of breast carcinoma in Pakistani females living in 
Lahore and Karachi, Liede and associates (2002) found 3337C>T mutation as the 
commonest BRCA2 mutation. This finding is corroborated by the subsequent 
discoveries by Farooq et al. (2011) who also found second new BRCA2 mutation, 
5057delTG. Both, however, are not founder mutations for this population. In the Far 
East, a founder BRCA2 mutation, 5802delAATT, has been reported in Japanese 
population (Ikeda et al. 2001). Another founder BRCA2 mutation, 7480C>T, was 
also discovered in Korean subjects by Seong and co-workers (2011). By far, Chinese 
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breast cancer subjects possess the highest number of founder mutations among far 
eastern population. Three founder mutations (3109C>T, 7436_7805del370 and 
9097_9098insA) have been reported by Kwong and colleagues (2012) in Southern 
Chinese population. This signifies that Far Eastern population has a higher 
probability of inheriting the defective copies of BRCA2 mutation which arise from a 
single ancestor. This is hardly surprising due to genetic inbreeding secondary to a  
higher prevalence of intra-racial marriage (or consanguineous marriage) practised by 
Far Eastern population than in other populations. Besides, similar pattern can also be 
observed in other populations that also practise inbreeding due to isolated 
geographical region and cultural similarities. For instance, nearly all known BRCA2 
mutation in Scandinavian populations are founder mutations (Jara et al. 2006, 
Soegaard et al. 2008) As a result, the aberrant BRCA2 mutation is preserved to the 
extreme which result in a higher number of founder mutations in Far Eastern females 
with breast carcinoma than their South Asian (Pakistani, Indian and Bangladeshi) 
counterparts.  
 In Malaysia, four BRCA2 mutations have been documented so far; 4859delA, 
4265delCT, 1342C.A, 490 delCT (Toh et al. 2008). The first two BRCA2 mutations 
are also the most common BRCA2 mutations among Filipinos breast cancer females 
(De Leon 2002). This finding is indeed very fascinating since such shared BRCA2 
mutations between two closely-related populations but living in two distinct 
geographical locations have been reported in other studies as well. For instance, the 
founder BRCA2 mutation, 999del5, has been reported in three ancestrally-related 
populations from three different countries (Iceland, Denmark and Finland) 
(Gunnarson et al. 2008, Hartikainen et al. 2007, Soegaard et al. 2008). Hence, these 
observations merit further research to ascertain whether these two BRCA2 mutations 
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are the founder mutations for both Malays and Filipinos individuals. As a corollary, 
it may also provide the concrete evidence that both Malays and Filipino breast 
cancer sufferers come from the same ancestral lineage. This may result in the 
construction of phylogenetic tree for BRCA2 mutation which will enable the current 
cancer researchers to design a highly-specific anti-cancer pharmacotherapy which 
will be effective in at least improving the survival breast cancer subjects in these two 
populations. Nevertheless, such endeavour has yet to be taken place and further 
works are required before such aspiration can be fully realized. As a summary, Table 















Table 2.1: Types of BRCA1 and BRCA2 mutations in selected populations of 
different ancestries (adapted from Karami &Mehdipour, 2013) 
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Table 2.1 continued... 
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2.4 ASSOCIATION BETWEEN BRCA1/BRCA2 MUTATIONS AND 
CLINICOPATHOLOGICAL CORRELATES 
2.4.1 General overview 
 It has been vastly documented that the BRCA1 mutation is associated with 
early-onset breast cancer, higher tumour grades and negative for hormonal receptors 
(i.e no oestrogen, progesterone and HER2/neu (ERBB2) receptors (Karp et al. 1997, 
Atchley et al. 2008). Despite all the above features are associated with dismal 
prognosis, the results from various studies are discrepant with several of them 
reporting grimmer prognosis (Brekelmans et al. 2006) whilst others documenting 
similar prognostic outlook (Rennert et al. 2007). 
   Distinct clinicopathological differences have been documented between 
BRCA1 and BRCA2-associated breast cancer. Kwong et al. (2009) showed the 
presence of BRCA1 mutations was significantly associated with bigger size of 
tumours (higher proportions of stage T2 and T3 tumours) and negative estrogen 
receptor (ER) status. No significant differences were found in terms of proportion of 
triple negative breast tumours between BRCA1 and BRCA2 mutation groups. These 
results are, however, at variance with the ones reported by Atchley et al., (2008) who 
reported a significantly higher proportion of triple negative breast cancer in those 
harbouring BRCA1 mutation. Apart from that, they also reported higher nuclear 
grades,  as assessed by  Black’s nuclear grading system, in those with BRCA1 
mutation when compared to BRCA2-associated cancer or non-carriers of both 
mutations (85.4% vs 56.5% vs 38.4%, p value <0.001). Interestingly, Atchley and 
associates (2008) also reported the use of hormonal replacement therapy is 
associated with higher number of BRCA2-associated tumour (BRCA1 vs BRCA2 
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mutations: 30.0% vs 9.3%, p value = 0.04). These findings are consistent with 
Turchetti et al. (2000) who established significant association between the presence 
of BRCA1 mutations and higher proliferative index (BRCA+ vs BRCA-: 100% vs 
46%, p value = 0.017), greater proportion of poorly differentiated tumour (BRCA+ 
vs BRCA-: 100% vs 44%, p value = 0.044) and greater percentage of negative 
estrogen receptor status (BRCA+ vs BRCA-: 100% vs 52%, p value = 0.020). This 
insuperable evidence provides the undisputable basis that the BRCA1 mutation is an 
adverse prognostic factor in breast cancer patients. 
 With respect to the incidence of primary ductal carcinoma in situ (DCIS), 
lesser proportion of DCIS was found among BRCA1 positive cases. A research 
endeavour led by Hamilton and associates (2004) at the Nottingham Breast Institute 
found none (0%) of the carriers of BRCA1 mutations were of DCIS histology whilst, 
on the other hand, 36% of those harbouring BRCA2 mutation were of positive for 
DCIS (p value = 0.010). This finding is corroborated by those of Marcus et al. 
(1996) who demonstrated BRCA1 mutation was significantly associated with a lower 
proportion of lobular carcinoma in situ (LCIS)  and atypical lobular hyperplasia 
(ALH) when comparison was made with BRCA2 mutation (2.7% vs 23.5% , p value 
= 0.010). The observations made by the Europen Breast Cancer Linkage Consortium 
further cemented the fact that DCIS and LCIS are rare entities in BRCA1 positive 
subjects (Breast Cancer Linkage Consortium 1997). This evidence, hence, confirms 
the scarcity of LCIS and DCIS in BRCA1 mutation carriers.. 
 There are also striking dissimilarities between BRCA1 and BRCA2 carriers 
with respect to the gene expression profiles of tumour tissues.  Based upon 
microarray data of breast cancer tissues, mammary carcinomas can be further 
subdivided into 4 distinct gene expression characteristics; basal-like, luminal-like 
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(both luminal A and luminal B), HER2/neu overexpressing and those resembling 
normal breast tissues (Hedenfalk  et al. 2001, Sorlie et al. 2003). The majority of 
BRCA1-associated breast cancers have basal-like features which are distinguishable 
by its high expression of cytokeratins 5, 6, 14 and 17, P-cadherin, EGFR, 
osteonectin, caveolin 1 and others (Honrado et al. 2006). This is in tandem with the 
high incidence of medullary and infiltrating carcinoma with medullary characteristic 
in BRCA1 carriers, both exhibit basal-like characteristics and triple negativity for 
ER, PR and HER2 status (Jacquemier et al. 2005, Rodriguez-Pinilla et al. 2007, 
Honrado et al. 2006). On the other hand, most BRCA2 mutation carriers are of 
luminal-like group (Larsen et al.  2013, Bane et al.  2008). 
2.4.2 Survival status in BRCA1 and BRCA2 mutation carriers 
With respect to overall survival status and other survival parameters (eg metastasis-
free survival, progression-free survival etc), the evidence, as described briefly in the 
previous section, is conflicting. Despite possessing poorer prognostic elements 
(aneuploidy, high rate of cell division, poorer degree of differention), no significant 
difference was shown between Ashkenazi Jewish females who carried BRCA1 
mutation and those who were non-mutation carriers in terms of hazard of death 
(Hazard ratio (HR) 0.76 (95% CI 0.45, 1.30), p value = 0.31) (Rennert et al. 2007). 
Besides, they also showed no statistically-significant higher hazard of death among 
the carriers of BRCA2 mutation when compared to the non-carriers (HR 1.31 (95% 
CI 0.80, 2.15) , p value = 0.28). These results are in contradiction to those of Kurian 
et al. (2010) who showed lower survival probability of reaching 70 years of age in 
BRCA1 mutation carriers than BRCA2 counterparts (53% and 71%, respectively). 
Nevertheless, the findings of Goodwin and associates (2012) negated what had been 
published by Kurian et al. (2010). They reported no significant differences were 
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noted between BRCA1 mutation carriers and sporadic breast cancer cases with 
respect to hazard of death or distant recurrences of breast tumours (HRdeath: 0.99 
(95% CI 0.62, 1.59), HRrecurrences: 0.83 (95% CI 0.51,1.83) ). Apart from that, upon 
analysis by multiple cox proportional hazard regression model, no significant impact 
of BRCA2 mutation was found on overall survival and distant breast cancer 
recurrences. Therefore, further studies are necessary to provide answers to this 
unsolved enigma. 
2.4.3 Mechanistic relationship between BRCA1 mutations and hormonal 
receptor status 
 There are a number of mechanisms through which BRCA1-related tumours 
cause marked deficiencies in the expression of estrogen and progesterone receptors. 
Firstly, the genetic alteration of BRCA1 may promote underexpression of estrogen 
receptors. This is evident from the observations of Hosey et al., (2007) who 
demonstrated a 5.4-fold (95% CI 2.6-fold, 40.1-fold, p value = 0.002) lowering of 
mean estrogen receptor 1 (ER1) gene expression in BRCA1-related breast cancer 
when compared to sporadic breast cancer. Besides that, another mechanism 
explaining the relationship between BRCA1 mutations with negative estrogen 
receptor status has been proposed by Fan and colleagues (1999). They theorized that 
BRCA1 mutation may perturb the intracellular signalling mediated by ligand-
activated estrogen receptor alpha (ER-α). This in turn will lead to the blocking of 
activation of AF2 portion of ER-α which may cause the repression of subsequent ER-
α expression. These findings had been corroborated by Ma et al. (2006) who showed 
that BRCA1 causes the downregulation of p300 expression, a known transcriptional 
co-activator of ER-α gene. 
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 Besides that, another interesting hypothesis has been put forward by a Liu et 
al., (1996) who demonstrated BRCA1 mutation is associated with disturbed normal 
differentiation of mammary tissues which may alter the phenotypes of breast cancer 
cells and increase the number of cells at risk for tumourigenesis. This supports the 
notion that BRCA1-associated breast cancer cells may raise from distinct progenitor 
cells other than the ones which are BRCA1-negative, resulting in ER positivity in the 
former and ER negativity in the latter. This is thus compatible with the previous 
findings that the presence of BRCA1 mutation is associated with basal-like 
carcinoma, a subtype of breast cancer that lacks estrogen and progesterone receptors. 
Besides that, King et al. (2004) also established BRCA1 haploinsufficiency is 
associated with marginally-insignificant reduced mean progesterone receptor 
expression when compared to BRCA2 cases (26.1 vs 9.6, p value = 0.06). 
Nevertheless, no experimental findings have so far conclusively elucidated how 
interaction between types of BRCA1 mutations and other crucial genetic mutations 
may give raise to ER and PR-negative breast tumours. More molecular works need 
to be done to supply these mechanistic lacunae of breast cancer pathogenesis with 
the necessary and verifiable experimental results. 
2.4.4 BRCA1 / BRCA2 mutation and clinicopathological correlates: Local 
perspectives 
For our local setting, it was Yip et al. (2009) who first successfully described 
the link between BRCA1 / BRCA2 mutation status and triple negative breast cancer. 
They demonstrated significantly higher proportions of ER and PR-negative breast 
cancer in BRCA1-associated breast cancer than BRCA2 ones in Malaysian setting 
(ER 93.3% vs 33.3%, p value =0.002; PR 100% vs 50%, p value =0.007). No 
significant difference was found with respect to HER2 negativity between BRCA1 
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and BRCA2-positive breast cancer (84.6% vs 80.0%, p value =0.774). Nevertheless, 
the results on HER2 receptor might be flawed since all indeterminate results 
(Immunohistochemistry grade 2) were discarded from analyses and Fluorescence In 
Situ Hybridization (FISH) was not employed to determine the indeterminate HER2 
results. Besides, only a small number of subjects possessing either BRCA1 or BRCA2 
mutations were included in the analyses (total frequencies of BRCA1 and BRCA2 
mutations positive are 16 and 15, respectively). Apart from that, the prevalences of 
genotypes for each newly-found BRCA1/BRCA2 mutations and the measures of 
associations (e.g such as odds ratio and 95% confidence intervals for odds ratio) 
between types of BRCA1 and BRCA2 mutatons with clinicopathological correlates 
have not been reported by Yip et al. (2009). Besides that, the effects of other well -
known determinants of hormone receptor status and histological types of breast 
tumours such as use of hormone replacement therapy, nulliparity and increasing age 
of first childbirth (Yang et al. 2011) were also not statistically controlled for using 
multivariable regression. Consequently, additional studies are needed to clearly 
characterize the relationship between clinicopathological features of breast tumours 
and types of BRCA1 and BRCA2 mutations in Malaysian setting. 
2.5 PROPHYLACTIC INTERVENTIONS FOR BRCA1 AND BRCA2 
MUTATIONS CARRIERS 
 There are several prophylactic treatments that have been advocated for those 
who are positive for BRCA1 or BRCA2 mutations. The strategies for breast cancer 
prophylaxis can be divided into two; medical and surgical approaches. With regard 
to the former, Narod and associates (2000) have found that the use of tamoxifen 
confers protection against contralateral mammary carcinoma in those harbouring 
BRCA1 mutations (OR 0.38, 95% CI 0.19, 0.74) and BRCA2 mutations (OR 0.63, 
